Minireviews
Copyright ©The Author(s) 2016.
World J Gastrointest Surg. Jan 27, 2016; 8(1): 84-89
Published online Jan 27, 2016. doi: 10.4240/wjgs.v8.i1.84
Table 1 Summary of the studies included in this review
Ref.Centres and aimNo. of patients (stenting/surgery)Stenting morbiditySurgery morbidityStenting mortalitySurgery mortalityStenting efficacy
Fiori et al[9]Single centre, palliation11/1101/11 (9%)00100%
Xinopoulos et al[7]Single centre, palliation15/15000093%
van Hooft et al[11]Multicentre, palliation11/1011/11 (100%)5/10 (50%)3/11 (27%)082%
Sankararajah et al[10]Single centre9/92/9 (22%)6/9 (67%)1/9 (11%)1/9 (11%)78%
Cheung et al[23]Single centre, bridge to surgery24/242/24 (8%)17/24 (71%)0083%
van Hooft et al[24]Multicentre, bridge to surgery47/5125/47 (53%)23/51 (41%)9/47 (19%)9/51 (18%)70%
Ho et al[15]Single centre, bridge to surgery20/197/20 (35%)11/19 (35%)03/19 (16%)70%
Young et al[6]Multicentre, palliative26/2610/26 (38%)14/26 (54%)0079%
Table 2 Surgeons’ treatment preferences in different clinical scenarios (Suen et al[8])
Clinical scenariosLevel of clinical certainty
Evidence of community equipoise?
Surgery (%)Undecided (%)Stent (%)
170yo; partial obstruction; metastatic cancer; ASA score 481280N
270yo; complete obstruction; metastatic cancer; ASA 49882N
350yo; partial obstruction; metastatic cancer; ASA 4151075N
450yo; complete obstruction; metastatic cancer; ASA 412880N
570yo; partial obstruction; metastatic cancer; ASA 1511930Y
670yo; complete obstruction; metastatic cancer; ASA 1401347Y
750yo; partial obstruction; metastatic cancer; ASA 1601723Y
850yo; complete obstruction; metastatic cancer; ASA 1511435Y
970yo; partial obstruction; curable cancer; ASA 4661519Y
1070yo; complete obstruction; curable cancer; ASA 4411346Y
1150yo; partial obstruction; curable cancer; ASA 4731017N
1250yo; complete obstruction; curable cancer; ASA 4501139Y
1370yo; partial obstruction; curable cancer; ASA 19640N
1470yo; complete obstruction; curable cancer; ASA 179129N
1550yo; partial obstruction; curable cancer; ASA 19640N
1650yo; complete obstruction; curable cancer; ASA 18794N